536 related articles for article (PubMed ID: 32243222)
21. Dose-adjusted EPOCH-rituximab or intensified B-NHL therapy for pediatric primary mediastinal large B-cell lymphoma.
Knörr F; Zimmermann M; Attarbaschi A; Kabíčková E; Maecker-Kolhoff B; Ruf S; Kühnle I; Ebinger M; Garthe AK; Simonitsch-Klupp I; Oschlies I; Klapper W; Burkhardt B; Woessmann W
Haematologica; 2021 Dec; 106(12):3232-3235. PubMed ID: 34498443
[No Abstract] [Full Text] [Related]
22. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas.
Voulgarelis M; Giannouli S; Anagnostou D; Tzioufas AG
Rheumatology (Oxford); 2004 Aug; 43(8):1050-3. PubMed ID: 15187246
[TBL] [Abstract][Full Text] [Related]
23. Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.
Jerkeman M; Aman P; Cavallin-Stahl E; Torlakovic E; Akerman M; Mitelman F; Fioretos T
Int J Oncol; 2002 Jan; 20(1):161-5. PubMed ID: 11743658
[TBL] [Abstract][Full Text] [Related]
24. Is Dose-Adjusted EPOCH-R Less Effective in Children Than Adults With Primary Mediastinal B-Cell Lymphoma?
Lakhotia R; Melani C; Roschewski M; Wilson WH
J Clin Oncol; 2022 Jun; 40(18):2063-2064. PubMed ID: 35377729
[No Abstract] [Full Text] [Related]
25. Primary B Cell Lymphoma of the Pancreas.
Kopel J; Swarup K; Thein K; Swarup S
J Gastrointest Cancer; 2020 Sep; 51(3):1077-1080. PubMed ID: 32418167
[No Abstract] [Full Text] [Related]
26. Late infections and secondary malignancies after bendamustine/rituximab or RCHOP/RCVP chemotherapy for B-cell lymphomas.
Olszewski AJ; Reagan JL; Castillo JJ
Am J Hematol; 2018 Jan; 93(1):E1-E3. PubMed ID: 28960532
[No Abstract] [Full Text] [Related]
27. Interim PET/CT Result Is Not Predictive of Survival in Patients With MYC-rearranged Non-Burkitt Aggressive B-cell Lymphoma.
Cherng HJ; Sargent RL; Nasta SD; Svoboda J; Schuster SJ; Mato AR; Schrank-Hacker A; Morrissette JJD; Landsburg DJ
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):673-678. PubMed ID: 30033208
[TBL] [Abstract][Full Text] [Related]
28. CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma.
Wilson KS; Sehn LH; Berry B; Chhanabhai M; Fitzgerald CA; Gill KK; Klasa R; Skinnider B; Sutherland J; Connors JM; Gascoyne RD
Leuk Lymphoma; 2007 Jun; 48(6):1102-9. PubMed ID: 17577773
[TBL] [Abstract][Full Text] [Related]
29. High-risk diffuse large B-cell lymphoma: can we do better than rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone?
George A; Tam CS; Seymour JF
Leuk Lymphoma; 2013 Dec; 54(12):2575-6. PubMed ID: 23597141
[No Abstract] [Full Text] [Related]
30. Application of the LymphGen classification tool to 928 clinically and genetically-characterised cases of diffuse large B cell lymphoma (DLBCL).
Runge HFP; Lacy S; Barrans S; Beer PA; Painter D; Smith A; Roman E; Burton C; Crouch S; Tooze R; Hodson DJ
Br J Haematol; 2021 Jan; 192(1):216-220. PubMed ID: 33010029
[No Abstract] [Full Text] [Related]
31. The Spectrum of MYC Alterations in Diffuse Large B-Cell Lymphoma.
Xia Y; Zhang X
Acta Haematol; 2020; 143(6):520-528. PubMed ID: 32074595
[TBL] [Abstract][Full Text] [Related]
32. Fulminant B hepatitis in a surface antigen and hepatitis B DNA-negative patient with diffuse large B-cell lymphoma after CHOP chemotherapy plus rituximab.
Yamagata M; Murohisa T; Tsuchida K; Okamoto Y; Tsunoda S; Nakamura M; Kusano K; Majima Y; Kuniyoshi T; Iijima M; Sugaya H; Hiraishi H
Leuk Lymphoma; 2007 Feb; 48(2):431-3. PubMed ID: 17325912
[No Abstract] [Full Text] [Related]
33. Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?
Abramson JS
Cancer; 2019 Sep; 125(18):3111-3120. PubMed ID: 31287161
[TBL] [Abstract][Full Text] [Related]
34. Pegylated liposomal doxorubicin in combination chemotherapy in the treatment of previously untreated aggressive diffuse large-B-cell lymphoma.
Avilés A; Neri N; Castañeda C; Talavera A; Huerta-Guzmán J; González M
Med Oncol; 2002; 19(1):55-8. PubMed ID: 12025891
[TBL] [Abstract][Full Text] [Related]
35. Double-hit diffuse large B-cell lymphoma.
Friedberg JW
J Clin Oncol; 2012 Oct; 30(28):3439-43. PubMed ID: 22949152
[No Abstract] [Full Text] [Related]
36. Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
Ennishi D; Jiang A; Boyle M; Collinge B; Grande BM; Ben-Neriah S; Rushton C; Tang J; Thomas N; Slack GW; Farinha P; Takata K; Miyata-Takata T; Craig J; Mottok A; Meissner B; Saberi S; Bashashati A; Villa D; Savage KJ; Sehn LH; Kridel R; Mungall AJ; Marra MA; Shah SP; Steidl C; Connors JM; Gascoyne RD; Morin RD; Scott DW
J Clin Oncol; 2019 Jan; 37(3):190-201. PubMed ID: 30523716
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.
Lin P; Dickason TJ; Fayad LE; Lennon PA; Hu P; Garcia M; Routbort MJ; Miranda R; Wang X; Qiao W; Medeiros LJ
Cancer; 2012 Mar; 118(6):1566-73. PubMed ID: 21882178
[TBL] [Abstract][Full Text] [Related]
38. Intra-vascular large B-cell lymphoma revealed by a nephrotic syndrome: a one year remission induced by a high frequency CHOP and rituximab.
Girard T; Nochy D; Montravers F; Der Sahakian G; Fior R; Galanaud P; Boué F
Leuk Lymphoma; 2004 Aug; 45(8):1703-5. PubMed ID: 15370230
[TBL] [Abstract][Full Text] [Related]
39. New high-risk molecular subtypes of DLBCL identified.
Killock D
Nat Rev Clin Oncol; 2019 Feb; 16(2):68. PubMed ID: 30560951
[No Abstract] [Full Text] [Related]
40. MYC rearrangement and MYC/BCL2 double expression but not cell-of-origin predict prognosis in R-CHOP treated diffuse large B-cell lymphoma.
Xu J; Liu JL; Medeiros LJ; Huang W; Khoury JD; McDonnell TJ; Tang G; Schlette E; Yin CC; Bueso-Ramos CE; Lin P; Li S
Eur J Haematol; 2020 Apr; 104(4):336-343. PubMed ID: 31944390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
